# Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Study · id `cardio:ct-nct02477969` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02477969](<https://clinicaltrials.gov/study/NCT02477969>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02477969

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 587 participants.

## Technical summary

Registry record NCT02477969. Randomized; triple masking; primary purpose treatment. Start 2014-02-27 (actual); primary completion 2016-06-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 587 participants (enrolled count; ClinicalTrials.gov record NCT02477969, source copy `cardio:ctgov-nct02477969-2017-01-24`, retrieved 2026-10-26)
- Started: 2014-02-27 (actual) (ClinicalTrials.gov record NCT02477969, source copy `cardio:ctgov-nct02477969-2017-01-24`, retrieved 2026-10-26)
- Primary completion: 2016-06-22 (actual) (ClinicalTrials.gov record NCT02477969, source copy `cardio:ctgov-nct02477969-2017-01-24`, retrieved 2026-10-26)
- Completion: 2017-06 (anticipated) (ClinicalTrials.gov record NCT02477969, source copy `cardio:ctgov-nct02477969-2017-01-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02477969, source copy `cardio:ctgov-nct02477969-2017-01-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02477969-2017-01-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): PEX168(100µg)
- Intervention (Drug): PEX168(200µg)
- Intervention (Drug): Placebo
- Intervention (Drug): Metformin
- Lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. (`cardio:org-jiangsu-hansoh-pharmaceutical-co-ltd`)

## Provenance

Content hash: ca9a86778c66a235ed2d630e6d5e53ab828d9440278225b75a0213369e048001
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
